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Abstract: 
Objective: This study reports follow-up data from a multi-centre randomized controlled trial (n=142) 
comparing the Maudsley Model of Anorexia Nervosa Treatment for Adults (MANTRA) with 
Specialist Supportive Clinical Management (SSCM) in outpatients with broadly defined anorexia 
nervosa (AN). At 12 months post-randomization, all patients had statistically significant 
improvements in body mass index (BMI), eating disorder (ED) symptomatology and other outcomes 
with no differences between groups. MANTRA was more acceptable to patients. The present study 
assessed whether gains were maintained at 24 months post-randomization.  
Methods: Follow-up data at 24 months were obtained from 73.2% of participants. Outcome measures 
included BMI, ED symptomatology, distress, impairment, and additional service utilization during the 
study period. Outcomes were analyzed using linear mixed models.  
Results: There were few differences between groups. In both treatment groups, improvements in 
BMI, ED symptomatology, distress levels and clinical impairment were maintained or increased 
further. Estimated mean BMI change from baseline to 24 months was 2.16kg/m2 for SSCM and 
2.25kg/m2 for MANTRA (effect sizes of 1.75 and 1.83 respectively). Most participants (83%) did not 
require any additional intensive treatments (e.g. hospitalization). Two SSCM patients became 
overweight through binge-eating.  
Discussion: Both treatments have value as outpatient interventions for patients with AN.   
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Two Year Follow-Up of the MOSAIC Trial: a Multi-Centre Randomised Controlled Trial 
Comparing Two Psychological Treatments in Adult Outpatients with Broadly Defined Anorexia 
Nervosa  
Until recently, only a handful of small-scale underpowered randomized controlled trials (RCTs) had 
been conducted in adults with AN1. Latterly, high quality studies2 and large-scale trials3 testing 
different outpatient treatments have emerged. Nonetheless, a recent systematic review on outpatient 
treatments for adults and older adolescents with AN concluded that so far, when comparing individual 
psychological therapies with each other, no specific treatment was consistently superior to any other 
specific approach4. The review recommended that larger RCTs of longer treatment duration and 
follow-up are needed.   
  
We recently published a large multi-centre trial5,6 (Maudsley Outpatient Study of Treatments for 
Anorexia Nervosa and Related Conditions; MOSAIC) comparing two outpatient treatments for adults 
with AN: one was the Maudsley Model of AN Treatment for Adults (MANTRA)7-11, the other 
Specialist Supportive Clinical Management (SSCM)12,13. Both treatments resulted in statistically 
significant improvements in body mass index (BMI) (with large within-group effect sizes at 12 
months) and reductions in ED symptomatology, other psychopathology and clinical impairment over 
time, but with no statistically significant difference between groups at either 6 months or 12 months 
post-randomization.  Improvements in neuro- and social-cognitive measures were less consistent. One 
SSCM patient died during treatment. Compared to SSCM, MANTRA patients rated their treatment as 
statistically significantly more acceptable and credible at 12 months. There was no difference between 
groups in additional service consumption. In the subgroup of participants who were more severely ill 
at baseline (i.e. had a BMI of below 17.5 kg/m2) MANTRA appeared to have a non-significant 
advantage both at 6 and 12 months in terms of greater increases in BMI.  
 
However, evidence from the first trial that used SSCM14 suggests that the effects of SSCM, i.e. the 
comparison treatment used here, may diminish over time, making the need for longer-term follow-up 
particularly pressing. In addition, MANTRA is a new treatment where longer-term outcomes are not 
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known. The aim of the present study therefore was to assess the longer-term outcomes (24 months 
post-randomization) of both treatments.     
 
METHODS: 
This is a 24-month follow-up study of a multi-centre two-arm superiority trial (the MOSAIC trial), 
which evaluates the efficacy, cost and cost-effectiveness of MANTRA versus SSCM in adult 
outpatients with AN.  Full details of the trial protocol can be found elsewhere5. The main hypothesis 
of the follow-up study was in line with that of the main study, i.e. MANTRA will be superior to 
SSCM in producing greater weight gain and greater improvement in eating-disorder related and other 
psychopathology in adults with broadly defined AN at 24-month follow-up. 
 
Details on participants, study procedures, assessments, sample size calculations, trial interventions 
and statistical analyses can be found in the online appendix.  
 
RESULTS 
The following measures were prioritised for follow-up analysis at 24 months: BMI, weight, Eating 
Disorders Examination18,19 (EDE; Global and Restraint, Eating concern, Shape Concern, and Weight 
Concern subscales), Depression Anxiety and Distress Scale-2120 (DASS), Obsessive Compulsive 
Inventory-Revised21 (OCI-R), and Clinical Impairment Assessment22 (CIA).  
 
Participant Flow and Baseline Characteristics:  
The baseline data can be found in our main paper6. The CONSORT diagram of the study is presented 
here (Figure 1). A total of 104/142 participants (73.2%) provided primary outcome data at 24 months, 
79.2% (57/72) in the MANTRA group and 67.1% (47/70) in the SSCM group. This difference was 
not statistically significant (p=0.105). Of the 38 patients with missing data, 11 had actively withdrawn 
from participation, one patient had died, and the remainder were lost to follow-up. All 142 initially 
randomized participants were included in the ITT analysis.  
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Treatment Outcomes: 
No baseline variables were found to be predictive of later missingness. As in our main paper6, only 
non-completion of treatment was predictive of loss to follow-up at 24 months: 54.75% of non-
completing participants compared to 13.68% of completers had missing primary outcome data at 24-
month follow-up (p<0.001). 
 
Table 1 shows estimated group differences at 24 months and the corresponding estimated means, 
standard errors and effect sizes, accounting for the fact that treatment adherence predicts missingness 
(using multiple imputation) and allowing for therapist effects.   
 
Mean BMI (primary outcome) did not differ significantly between groups at 24 months (p=0.85) and 
the between group effect size was small (standardized coefficient 0.08). Figure 2 shows predicted 
mean BMI at all three post-randomization time points (originating from the observed mean at 
baseline). On inspection of the data it became clear that the SSCM mean had been driven up by two 
patients with BMIs of 25 and 29 kg/m2, in both cases through binge eating. We re-ran the BMI 
analysis removing the two outliers. The predicted mean outcome for MANTRA was 18.73 (SE 0.39) 
and for SSCM was 18.33 (SE 0.39) kg/m2 (p=0.38). (Note: Outcomes in both groups are slightly 
different from before as the multiple imputation data sets were different, as the observations from the 
outliers couldn’t be used to help impute missing data.) The estimated mean outcome change from 
baseline to 24 months was 2.11 kg/m2 for MANTRA (p<0.001) and for SSCM was 1.73 kg/m2 
(p<0.001). 
 
 
Mean EDE Global score also did not differ significantly between groups at 24 months (p=0.97). Nor 
did most of the other secondary outcomes with the exception of the OCI-R where there was a 
statistically significant difference between groups, favoring SSCM. Associated standardized between 
group effect sizes were small to moderate (Cohen’s d0.36).  
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Table 2 shows estimated mean outcome change and associated within-group effect sizes from baseline 
to 24 months by group. There was a statistically significant improvement in BMI in both groups after 
commencing treatment, with mean BMI in the MANTRA group estimated to increase from baseline 
to month 24 by 2.25 (95% CI 1.42 to 3.09). Respective figures in SSCM were 2.16 (95% CI 1.34 to 
2.98).  In both groups, there was also statistically significant change between baseline and 24 months 
for EDE Global and most EDE subscale scores (with the exception of Eating Concern), DASS, OCI-R 
and CIA scores. Associated effect sizes were either very large to large (BMI, EDE global score, 
DASS and CIA) or medium (EDE: weight, shape and restraint scores, OCI-R). 
 
Recovery Rates 
Our definitions of recovery and partial recovery were based on those previously used in other studies2 
and were as follows: recovered: BMI>18.5 kg/m2 and EDE Global Score <2.77; partially recovered: 
BMI<17.5 kg/m2 and EDE<2.77 or BMI between >17.5 kg/m2 and ≤18.5 kg/m2 or BMI>18.5 kg/m2 
and EDE>2.77; not recovered: BMI≤17.5 kg/m2 and EDE>2.77.  Recovery rates by group at 24 
months were calculated in two ways. Firstly, as proportions of actually available data (n=102 
participants; MANTRA, n=56; SSCM, n=46) and secondly with the full baseline number (n=142) of 
participants as the denominator (ITT sample).  
 
Proportions calculated based on available data were as follows: In MANTRA 18/56 (32.15%) were 
fully recovered, 32/56 (57.15%) partially recovered and 6/56 (10.7%) not recovered. In SSCM 13/46 
(28.3 %) were fully recovered, 26/46 (56.5%) were partially recovered and 7/46 (15.2%) not 
recovered. 
 
When proportions were calculated based on ITT data they were as follows: In MANTRA 18/72 (25%) 
were fully recovered, 32/72 (44.4%) were partially recovered, 6/72 (8.3%) were not recovered and 
16/72 (19.4%) were missing. In SSCM 13/70 (18.6 %) were fully recovered, 26/70 (37.1%) were 
partially recovered, 7/70 (10%) not recovered and 24/70 (34.3%) were missing. 
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Subgroup analyses 
Two subgroup analyses were conducted. Firstly, the sample was restricted to those with baseline BMI 
below 17.5 kg/m2 (MANTRA: n=56; SSCM: n=49) because our two previous studies6,11 suggested 
that MANTRA may be advantageous in more underweight patients. The cut-off of a BMI below 17.5 
was chosen as it is part of the ICD-10 criteria33 for AN and also for comparability with other studies2. 
At 24 months, in this more severe group, the BMI difference was 0.45 kg/m2 (p=0.43, 95% CI -0.154 
to 0.65) in favor of MANTRA. The predicted BMI changes were 2.48 kg/m2 and 2.04 kg/m2 for those 
in the MANTRA and SSCM groups respectively. 
 
Secondly, to evaluate the effect of treatment receipt, another subgroup analysis included only 
treatment completers (MANTRA: n=54, SSCM: n=41). In the completers the BMI difference at 24 
months was 0.38 kg/m2 (p=0.42, 95% CI -1.3 to 0.54) in favor of MANTRA. 
 
Additional Service Utilization  
A full cost-effectiveness analysis will be presented elsewhere. We consider here only intensive (i.e. 
hospital-based) treatments, such as in-patient admissions for the ED or for psychiatric comorbidities 
or day-care/home treatments, as these are the biggest cost drivers. During the whole 24 month period, 
24 patients (16.9%; 12 in each treatment group) had additional intensive treatment. Of these, 17 
patients had ED treatment (8 MANTRA, 9 SSCM) and 7 others only received psychiatric treatment  
(4 MANTRA, 3 SSCM). Days of treatment ranged from 3 to 366. In the MANTRA treatment group, 
between baseline and 12 months, eight patients had additional psychiatric treatment; three of these 
also had additional treatment during months 13 to 24. Four additional MANTRA patients had 
intensive treatment during year 2 (month 13 to 24) only.  In SSCM, between baseline and 12 months 
ten patients had additional psychiatric treatment, five of these also needed additional treatment 
between 13 and 24 months. Two additional patients needed intensive treatment during year two (13 to 
24 months).  There were no statistically significant differences between treatment groups in numbers 
of people receiving intensive treatment or in mean number of additional treatment days.  
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DISCUSSION 
Our hypothesis that MANTRA would be superior to SSCM at 24 months in terms of clinical 
outcomes was not confirmed. In both groups, however, improvements made at 12 months in terms of 
BMI, ED symptoms and secondary outcomes were either maintained or increased further by 24 
months. Estimated mean BMI change from baseline to 24 months was 2.16 kg/m2 for SSCM and 2.25 
kg/m2 for MANTRA patients, with associated effect sizes of 1.75 and 1.83 respectively. There were 
no overall group differences in outcomes, except on the OCI-R where there were greater 
improvements in the SSCM group. 
 
Importantly, in SSCM there was no suggestion that improvements diminish over time. The previous 
study in which SSCM’s effects seemed to diminish over time was much smaller, but the follow-up 
period was longer, with only 12 patients assessed at the 5-year follow-up14.  
 
Full recovery rates in both treatments were modest, at 25% to 32.2% for MANTRA and 18.6% to 
28.3% for SSCM, depending on which denominator was used. Perhaps these modest recovery rates 
are not surprising given that our study included patients with very low baseline BMIs, provided they 
were medically stable. The lowest BMI at baseline was 13.4 kg/m2.  Our definition of recovery is 
potentially limited by the fact that people up to BMI 18.5 kg/m2were included in the trial and that 
having a BMI above 18.5 kg/m2 together with a normal EDE global score was counted as fully 
recovered. Theoretically, this leaves open the possibility that people could be counted as being 
recovered despite having minimal weight gain only. However, this was not the case: We checked the 
13 patients who had a BMI between 18.5 and 19.0 kg/m2 at two-year follow-up, i.e. those who were 
candidates for having recovered with minimal weight gain. They had a mean BMI increase of 2.14 (+ 
0.76) kg/m2. The BMI increase in this group from baseline to 24 months ranged from 1.07 to 3.65 
kg/m2. 
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Across both groups, most participants (83%) did not need any additional intensive treatment, such as 
in-patient or day-care treatment for their eating disorder or other psychiatric in-patient care. This is an 
important finding, as in-patient and day-care treatments are the main cost-drivers in the treatment of 
AN.  
 
Subgroup analyses of more severely ill patients and of treatment completers continued to show a non-
significant trend favoring MANTRA.  
 
Whilst for most patients outpatient treatment was a safe and beneficial treatment option, there were 
also some harms noted. As previously reported, there was one death in the SSCM group and, also in 
SSCM, two patients became overweight through binge eating. The latter deserves comment, as 
uncontrollable weight gain is what AN patients themselves fear most. It is possible that SSCM 
patients may not have been as well equipped as MANTRA patients in dealing with urges to binge, due 
to this treatment’s lack of emphasis on teaching skills beyond regular eating. However, the numbers 
are too small to reach any firm conclusions here.  
 
Our findings can most readily be compared against those from two other recent studies - one is the 
Oxford case series of enhanced CBT (CBT-E; n=50) by Fairburn et al.2, the other the ANTOP study 
(n=242)3 from Germany, where patients received either focal psychodynamic therapy, CBT-E or 
optimized treatment as usual. In both studies, patients had a broadly similar average illness severity to 
ours at baseline, in terms of their BMI (Fairburn et al.2: 16.5 kg/m2; ANTOP study3: 16.7 kg/m2. 
Having said that there were important differences between these studies in terms of illness duration, 
with the Fairburn study2 having a much shorter illness duration (mean 3 years) compared to the 
ANTOP study3 and the MOSAIC trial6 where the illness duration was around 7 years. Moreover, the 
inclusion criteria of these studies were quite different, with the Fairburn study2 including patients with 
a BMI between 15 and 17.5 kg/m2 and the ANTOP study3 including patients with a BMI between 15 
and 18.5 kg/m2, whereas in the MOSAIC trial more severely underweight patients were included, too. 
Follow-up assessment in the Fairburn study2 was conducted at 23 months and in the ANTOP study3 at 
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22 months. In the Fairburn study2, mean BMI change from baseline to follow-up was 1.7kg/m2, 
whereas in the ANTOP study3 this was 1.64, 1.30, and 1.22 kg/m2 respectively for focal 
psychodynamic psychotherapy, CBT-E, and optimized treatment as usual. In our study, the BMI 
change was 2.25 kg/m2 for MANTRA and 2.16 kg/m2 for SSCM at 24 months. If one only looks at 
the MOSAIC sub-group with initial BMI below 17.5 kg/m2 (for easier comparison with the Fairburn 
study2), BMI change from baseline to 24 months is 2.5 and 2.0 kg/m2 for MANTRA and SSCM. 
Thus, compared to best available recent other studies our BMI outcomes at 24 months are excellent.  
 
In our trial the dose of treatment was more modest and tailored to the illness severity of patients 
compared to these other two studies2,3, where 40 sessions of treatment were routinely offered. 
However, this did not translate into greater need for hospitalization in our study compared to the 
ANTOP study where in focal psychodynamic therapy 19% of the patients required inpatient 
treatment, in CBT-E 29%, and in TAU-O 40%. In the Fairburn study2, additional intensive treatment 
was needed in 13/50 (22.6%) of cases.   
 
As previously reported, MANTRA was assessed as statistically significantly more acceptable and 
credible by patients at 12 months6 and there were higher treatment completion rates and higher 
research assessment completion rates up to 24 months. Overall outcomes in both treatments were 
similar, and at least comparable to those of other recent trials, but MANTRA may have advantages for 
those with a more severe illness. Finally, a small number of SSCM patients experienced harms, 
whereas no harms were noted in MANTRA. In conclusion, both MANTRA and SSCM can be 
recommended as outpatient treatments for adults with AN.   
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Figure 1. CONSORT flow diagram 
Reprinted and updated with APA permission (originally printed in Schmidt et al.,6) 
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Figure 2. Predicted mean BMI at all three post-randomization time points (originating from observed 
mean at baseline). Covariates were fixed at mean baseline level of BMI (16.69), restrictive AN and no 
previous hospital admissions. 
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Online Appendix 
Participants:  
All available participants of the MOSAIC trial were contacted for participation in the follow-up study. 
Participants in this trial initially were recruited from consecutive new referrals to the outpatient 
services of four specialist UK Eating Disorders Services in London and Oxford, namely the South 
London and Maudsley National Health Service (NHS) Foundation Trust Specialist Eating Disorders 
Unit (n=84), the North East London Foundation Trust Eating Disorders Service (n=10), the Barnet, 
Enfield & Haringey Mental Health NHS Trust (n=21) and the Oxford Health NHS Foundation Trust 
(n=27). 
 
Inclusion criteria of the MOSAIC trial were as follows: Male or female, aged between 18 and 60 
years; with a BMI of 18.5 kg/m2 or below; and a DSM-IV diagnosis of AN or Eating Disorder Not 
Otherwise Specified (EDNOS)15, thus we used a broad definition of AN. Our definition of EDNOS 
included people who fulfilled all criteria of AN, except the weight criterion; those who fulfilled all 
criteria for AN but still had menses; those without a fat phobia; and those with partial AN (defined as 
having features of AN but missing at least two of the four diagnostic criteria)16. 
 
Exclusion criteria for the MOSAIC trial were: Life-threatening AN requiring immediate inpatient 
treatment as defined in the NICE guidelines17; insufficient knowledge of English to understand the 
treatment; learning disability; severe mental or physical illness which needed treatment in its own 
right (e.g. psychosis, diabetes mellitus); substance dependence or pregnancy. The trial did not exclude 
patients on antidepressants, provided they were on a stable dose, i.e. ≥four weeks. 
 
Study Procedures:  
Ethical approval for the MOSAIC Trial was obtained from Central London REC 4, National Research 
Ethics Service, Royal Free Hospital, London, NHS REC Reference: 10/H0714/9. This included 
ethical approval for the 24-month follow-up.  
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The trial was registered with Current Controlled Trials (ISRCTN67720902; URL: 
http://www.controlled-trials.com/ISRCTN67720902). 
 
Assessments:  
Assessments took place at 24 months after randomization. Assessors were blind to patient treatment 
allocation.  
 
Measures:  
The measures used at the 24 months assessment were the same as those at previous assessment points 
(pre–treatment [baseline], post-treatment [6 months] and short-term follow up [12 months]). 
 
Primary Outcome: 
Body mass index: Patients’ height had been recorded at baseline assessment. Patients’ weight was 
obtained at 24 months assessment.  
 
Secondary Outcomes: 
Eating Disorders Examination (EDE) global and subscale scores18. The EDE is a widely used, semi-
structured interview that generates four subscale scores: dietary restraint, eating concern, weight 
concern and shape concern. These four subscales are used to create a global score. For patients 
unwilling/unable to do the EDE interview, the questionnaire form of this assessment (EDE-Q) was 
used. The EDE-Q has been found to have similar validity to the EDE interview19.  
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Other psychopathology: We used the Depression, Anxiety and Stress Scale-21 (DASS-21)20 and the 
Obsessive Compulsive Inventory-Revised (OCI-R)21. The DASS is a 21-item self-report measure that 
assesses mood state over the past seven days using a 4-point Likert scale. The total score can be used 
as a measure of general distress. The OCI-R is an 18-item questionnaire which uses a 5 point forced 
choice severity scale and provides a single global score (max score=72).  
 
Psychosocial impairment: The Clinical Impairment Assessment (CIA)22. This is a self-report measure 
of global psychosocial impairment resulting from the individual’s ED behaviors. 
 
Neurocognitive and social-cognitive measures: The Wisconsin Card Sorting Task23 and the Brixton 
Spatial Anticipation Task24  assess cognitive flexibility (set-shifting ability). The Rey-Osterrieth 
Complex Figure Test25,26 is a test of central coherence and evaluates ability to plan, organize and 
assemble complex information. Baron-Cohen’s ‘Reading the Mind in Film’ task27 assesses 
participants’ Theory of Mind. The levels of missing data were too high at 24 months to include these 
following measures in analyses. 
 
Service use: The number of MANTRA and SSCM sessions were recorded by therapists on a case 
record form. Patients completed the Client Services Receipt Inventory (CSRI)28, a self-report measure 
of service use, adapted for the current study to cover a wide variety of hospital, mental health, and 
community-based services as well as medications, impact of employment and additional personal 
expenditure due to the ED. CSRI data will be reported separately. In addition, patients’ electronic 
hospital records were used to obtain data on service utilization during the follow-up period.  
 
Sample Size Calculation:  
We estimated a 25% loss-to-follow up by 24 months and a resulting available sample size of 
142*0.75/2=53 patients per group. With this sample size we would have 90% power to detect a 
standardized treatment effect of Cohen’s d=0.64 and 80% power to detect an effect of d=0.55 or 
larger (two-sample t-test, 5% significance level). Assuming a standard deviation of weight gain of 4 
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kgs, these effect sizes translate into additional weight gains of 2 kgs and 2.56 kgs under MANTRA 
respectively and we previously argued that extra weight gains in this range are both realistic and 
clinically significant (see MOSAIC protocol5). 
 
Trial Interventions:  
Although patients in the current follow-up study no longer received the MOSAIC trial interventions, 
for ease of reference we have included some information on the content and duration of these. Further 
details, e.g. regarding therapist training and supervision, can be found in the trial protocol paper5.  
 
Following randomization, patients were offered either 20 once-weekly sessions of MANTRA or 
SSCM followed by 4 once-monthly follow-up sessions. In addition, patients in both arms were 
offered up to 4 sessions with a dietician and 2 joint sessions with a carer/close other. Patients with a 
BMI of ≤15 kgs/m2 were offered 30 weekly sessions of therapy and similar additional and follow-up 
sessions.   
 
MANTRA: This is an AN-specific therapy that targets four factors, linked to underlying obsessional 
and anxious/avoidant personality traits, thought to maintain the illness and therefore addressed in 
treatment. These are: a thinking style characterized by inflexibility, attention to detail at the expense 
of the bigger picture and fear of making mistakes; impairments in the socio-emotional domain (such 
as avoidance of the experience and expression of emotions); pro-anorexia beliefs (positive beliefs the 
person has about the utility of AN in helping them manage their life, e.g. AN keeps me safe); and the 
often inadvertently unhelpful response of close others, including emotional over-involvement, 
avoidance or criticism/hostility. 
 
MANTRA is centred around a patient-manual [unpublished], the use of which is tailored to the needs 
of the individual9. The therapist style is that of motivational interviewing, that is, reflective and 
collaborative. After an in-depth physical, psychological, neurocognitive and socio-
emotional/relational assessment, a collaborative case formulation is developed. Feedback, for 
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example, about medical risk, and thinking style is used to build motivation to change. The principles 
of behavioural change are used to guide people towards recovery. There is a clear hierarchy of 
treatment procedures depending on the person’s clinical profile and balancing treatment motivation, 
level of medical risk, and personal resources and supports available. 
 
SSCM: This treatment was developed as a comparison treatment in an RCT comparing CBT, 
interpersonal therapy and SSCM12-14. SSCM is designed to be delivered by ED specialists and aims 
‘to mimic outpatient treatment that could be offered to individuals with AN in usual clinical practice’. 
This treatment links features of clinical management and supportive psychotherapy. SSCM 
emphasizes safe and appropriate patient management and care, including education and support, and a 
positive and accepting therapeutic stance. The abnormal nutritional status and dietary patterns of AN 
are seen as central to SSCM. The treatment emphasizes the resumption of normal eating and 
restoration of weight and provides information on weight gain and weight maintenance strategies, 
energy requirements and relearning to eat normally. The remaining therapy content is determined by 
the patient. Further details of this treatment are described elsewhere12,13. There is also a manual for 
therapists [McIntosh et al. unpublished], which contains psycho-educational handouts. 
 
Statistical Analyses 
All statistical analyses were based on the intention-to-treat principle using Stata 1229. All outcomes 
were analyzed using linear mixed models and using the same model structures as in the primary 
paper6. The dependent variable was the outcome at 24 months, and the (fixed) explanatory variable of 
interest was trial arm. The models also included the baseline values of the variable under investigation 
and the randomization stratifiers BMI, AN subtype, and previous ED inpatient admission30,6 as further 
explanatory variables. In addition, the model contained random effects for therapists in the two 
treatment groups to allow for correlation in outcomes related to treatment being facilitated by the 
same therapist. The variance of these random effects was allowed to vary between treatment groups 
by including an interaction between therapist and treatment group. 
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Some missing values were present in the outcome variables. Following the approach laid out in 
Schmidt et al.6, we empirically assessed whether a number of baseline variables were predictive of 
missing values in the outcome variables, and also checked whether nonadherence to treatment (coded 
“1” = completed at least 15 therapy sessions, “0” = did not complete intervention) was predictive of 
loss to follow up. Out of these, only nonadherence was found to be an empirical predictor (see the 
Results section). To allow for such a missing data generating process, multiple imputation (MI) using 
chained equations was implemented (Stata command ice31). The imputation step of the procedure used 
treatment group, baseline value, randomization stratifiers, outcome at other time points, adherence, 
and therapist dummy variables to predict missing post-randomization outcome values. Here, the 
benefit of MI lies in its ability to incorporate post-randomization variables that are not part of the 
analysis model (treatment nonadherence) in the imputation step, and so enables an analysis that is 
valid under a more realistic missing-at-random assumption32. To minimize Monte Carlo error, 50 
imputations were used.  
 
Subgroup analyses were used to assess the estimated treatment effects among study participants with 
a baseline BMI below 17.5kg/m2, and among treatment completers. 
